Table 2 Histopathological findings in liver biopsies pre- and post-DAA therapy.

From: Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome

HCV pt #

Biopsya

MHAIb (n/18)

Fibrosisc stage (n/6)

CPAc %

Steatosis %d (pathologist)

Steatosis %d (visiopharm)

Duration between pre- and post-Tx Bx (mos)

Duration between SVR and post-Tx Bx (mos)

1

Pre-Tx

7

3

14.911

1

0

54.8

14.2

Post-Tx

5

2.5

13.461

1

0

  

2

Pre-Tx

9

2

5.299

40

6.994

16.6

9.4

Post-Tx

4

2

11.596

20

1.555

  

3

Pre-Tx

3

1

1.613

0

0

70.2

17.5

Post-Tx

2

0.5

3.009

0

0

  

4

Pre-Tx

8

6

6.744

5

0.861

85.8

28.4

Post-Tx

4

6

32.024

60

6.321

  

5

Pre-Tx

4

1

6.661

0

0

20.8

19.2

Post-Tx

1

1

3.496

0

0

  

6

Pre-Tx

2

1

3.677

0

0

15.3

6.0

Post-Tx

0

1

2.905

0

0

  

7

Pre-Tx

5

3

5.781

10

1.231

26.8

24.1

Post-Tx

2

1

6.767

10

2.735

  

8

Pre-Tx

3

2

8.021

15

0.183

24.6

20.1

Post-Tx

1

1

1.265

 < 5

0.597

  

9

Pre-Tx

nd

nd

nd

nd

nd

nd

26.0

Post-Tx

1

1.5

7.461

10

nd

  

10

Pre-Tx

8

4.5

15.664

5

1.248

21.1

15.3

Post-Tx

3

4

14.362

2

0.201

  

*P value

 

0.001

0.063

1.0

0.875

0.459

  
  1. DAA: direct-acting antiviral; HCV: hepatitis C virus; Pt: patient; Pre-Tx: pre-DAA treatment; Post-Tx: post-DAA treatment; MHAI: modified hepatitis activity index; CPA: collagen proportionate area; Bx: biopsy; Mos: months; nd: not done.
  2. *P values < 0.05 were considered statistically significant.
  3. aLiver biopsies were collected from patients with HCV pre- and post-DAA treatment.
  4. bWe used the MHAI to grade the amount of hepatitis activity (scale of 0 to 18).
  5. cFibrosis staging was first evaluated using light microscopy and the Ishak criteria (scale of 0 to 6). Then, CPA was calculated for each liver biopsy using a previously published method19,25,26. The percentage of hepatocytes involved by macrovesicular steatosis was first estimated by a pathologist (H.L.S.) and then quantified using a custom trained algorithm “Eq. (2)” (Visiopharm).
Back to article page